Chintan Chauhan - Par Drugs Chief Officer
| PAR Stock | 294.05 12.65 4.50% |
Insider
Chintan Chauhan is Chief Officer of Par Drugs And
| Age | 41 |
| Address | 816, Nilamber Triumph, Vadodara, India, 390007 |
| Phone | 91 26 5299 1022 |
| Web | https://www.pardrugs.com |
Par Drugs Management Efficiency
The company has return on total asset (ROA) of 0.1384 % which means that it generated a profit of $0.1384 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2084 %, meaning that it generated $0.2084 on every $100 dollars invested by stockholders. Par Drugs' management efficiency ratios could be used to measure how well Par Drugs manages its routine affairs as well as how well it operates its assets and liabilities. As of November 23, 2024, Total Assets is expected to decline to about 763.9 M. In addition to that, Non Current Assets Total is expected to decline to about 311.6 MSimilar Executives
| Showing other executives | INSIDER Age | ||
| Arun B | Oil Natural Gas | 62 | |
| Srikanth Venkatachari | Reliance Industries Limited | 58 | |
| Sethuraman | Reliance Industries Limited | 77 | |
| Madhu Chhibber | HDFC Bank Limited | N/A | |
| BE PGDM | Reliance Industries Limited | 64 | |
| Mukesh Ambani | Reliance Industries Limited | 67 | |
| Ramesh Lakshminarayanan | HDFC Bank Limited | 53 | |
| Rajni Jain | Oil Natural Gas | N/A | |
| Kamal Sharma | Oil Natural Gas | 62 | |
| Anurag Sharma | Oil Natural Gas | 61 | |
| Vivek Tongaonkar | Oil Natural Gas | 58 | |
| Savithri Parekh | Reliance Industries Limited | N/A | |
| Rakesh Singh | HDFC Bank Limited | 54 | |
| Pankaj Kumar | Oil Natural Gas | 58 | |
| Bhavesh Zaveri | HDFC Bank Limited | 58 | |
| Ajit Shetty | HDFC Bank Limited | N/A | |
| Srinivasan Vaidyanathan | HDFC Bank Limited | 60 | |
| Sunil Jain | Oil Natural Gas | 66 | |
| Sanjiv Singh | Reliance Industries Limited | 64 | |
| Pawan Kapil | Reliance Industries Limited | 77 | |
| Sashidhar Jagdishan | HDFC Bank Limited | 59 | |
Management Performance
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.14 |
Par Drugs And Leadership Team
Elected by the shareholders, the Par Drugs' board of directors comprises two types of representatives: Par Drugs inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Par. The board's role is to monitor Par Drugs' management team and ensure that shareholders' interests are well served. Par Drugs' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Par Drugs' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jignesh Savani, CEO Director | ||
| Chintan Chauhan, Chief Officer | ||
| Ghanshayambhai Savani, Whole Director | ||
| Sanket Trivedi, Company Officer | ||
| Falgun Savani, Chairman MD |
Par Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Par Drugs a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.21 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.30 % | ||||
| Current Valuation | 3.43 B | ||||
| Shares Outstanding | 12.3 M | ||||
| Price To Book | 3.74 X | ||||
| Price To Sales | 3.48 X | ||||
| Revenue | 956.4 M | ||||
| Gross Profit | 457.57 M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in Par Stock
Par Drugs financial ratios help investors to determine whether Par Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Par with respect to the benefits of owning Par Drugs security.